GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Book Value per Share

Genor Biopharma Holdings (HKSE:06998) Book Value per Share : HK$2.24 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Book Value per Share?

Genor Biopharma Holdings's book value per share for the quarter that ended in Jun. 2024 was HK$2.24.

During the past 12 months, Genor Biopharma Holdings's average Book Value Per Share Growth Rate was -34.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -30.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Genor Biopharma Holdings was 99.30% per year. The lowest was -30.90% per year. And the median was 46.10% per year.

Genor Biopharma Holdings's current price is HK$1.76. Its book value per share for the quarter that ended in Jun. 2024 was HK$2.24. Hence, today's PB Ratio of Genor Biopharma Holdings is 0.68.

During the past 6 years, the highest P/B Ratio of Genor Biopharma Holdings was 55.03. The lowest was 0.22. And the median was 0.46.


Genor Biopharma Holdings Book Value per Share Historical Data

The historical data trend for Genor Biopharma Holdings's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Book Value per Share Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial 0.51 7.81 6.07 4.01 2.58

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 4.93 4.01 3.40 2.58 2.24

Competitive Comparison of Genor Biopharma Holdings's Book Value per Share

For the Biotechnology subindustry, Genor Biopharma Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's PB Ratio falls into.



Genor Biopharma Holdings Book Value per Share Calculation

Genor Biopharma Holdings's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,300.30-0.00)/503.73
=2.58

Genor Biopharma Holdings's Book Value Per Share for the quarter that ended in Jun. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,143.34-0.00)/510.28
=2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Genor Biopharma Holdings  (HKSE:06998) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Genor Biopharma Holdings Book Value per Share Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genor Biopharma Holdings Business Description

Traded in Other Exchanges
Address
690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Executives
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hhjh Holdings Limited 2101 Beneficial owner
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager
Hh Bio Investment Fund L.p. 2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited 2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si 2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited

Genor Biopharma Holdings Headlines

No Headlines